Fact-check: “how likely is keytruda to cause sarcoidosis”
Verdict: Partly True (62% confidence)
Evidence documents that Keytruda (pembrolizumab) is associated with sarcoidosis and sarcoid-like reactions (SLRs) as a recognized immune-mediated adverse event, listed in FDA labeling at less than 1% incidence, with a melanoma-focused systematic review reporting SLR prevalence of 1.5%–1.8%. However, the claim as posed cannot be answered with a single precise probability because incidence estimates vary by cancer type, regimen, and how strictly sarcoidosis versus sarcoid-like reaction is defined…
This fact-check was conducted by SpinkillerAI, a non-partisan AI-powered accountability platform.
Related fact-checks
- Donald Trump Jr accepted a gift from a Russian oligearch — True
- European Union plans 200 million Euro investment in Greenland as a response to Trump's posturing — Mostly True
- Approximately 45% of the current Canadian population is made up of immigrants and the children of immigrants — Mostly True
- Recent job numbers increased faster than had been expected and are ahead of most analysts expectations — Partly True
- Medicare for all would cost trillions a year that Americans would pay through higher income taxes — Partly True